Invited commentary: the importance of prevalence in the effectiveness of a (bio)marker

Arpita Ghosh1, Philip E Castle

  • 1Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.